ARCA Biopharma IncABIO
A clinical-stage biopharmaceutical company developing precision therapies for cardiovascular diseases, including a recombinant fusion protein for heart failure and a genetically targeted treatment for atrial fibrillation. Its lead programs target specific patient populations defined by genetic markers, which distinguishes it from broader cardiovascular drug developers. Investors track the company for its potential in the emerging field of genotype-guided cardiovascular medicine.
Congressional Interest in ARCA Biopharma Inc (ABIO)
2 members of Congress have disclosed 2 trades in ARCA Biopharma Inc (ABIO), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Who in Congress Is Trading ABIO?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-06-04 | MICHAEL T. MCCAUL | buy | $50K-$100K |
| 2016-01-20 | JAMES B. RENACCI | buy | $1K-$15K |